

IN THE CLAIMS:

1-5. (Canceled)

6. (Currently amended) An isolated polypeptide selected from ~~the listing consisting of:~~

- (i) a polypeptide ~~having~~ comprising an amino acid sequence substantially as set forth in SEQ ID NO: 7 or SEQ ID NO: 9 ~~or a sequence having 47% or greater similarity to SEQ ID NO: 7 or SEQ ID NO: 9; or~~
- (ii) a polypeptide encoded by a nucleotide sequence substantially as set forth in SEQ ID NO: 6 or SEQ ID NO: 8, ~~or a sequence encoding an amino acid sequence having 47% or greater similarity to SEQ ID NO: 7 or SEQ ID NO: 9;~~
- ~~(iii) a polypeptide encoded by a nucleic acid molecule capable of hybridizing to the nucleotide sequence set forth in SEQ ID NO: 6 or SEQ ID NO: 8 under low stringency conditions and which encodes an amino acid sequence having 47% or greater similarity to SEQ ID NO: 7 or SEQ ID NO: 9;~~
- ~~(iv) a polypeptide as defined in part (i) or (ii) or (iii) in homodimeric form; and~~
- ~~(v) a polypeptide as defined in part (i) or (ii) or (iii) in heterodimeric form.~~

7. (Original) An isolated polypeptide according to claim 6 in multimeric form with itself or with another molecule.

8. (Original) An isolated polypeptide according to claim 7 wherein said other molecule is a molecule capable of promoting cell survival and/or delaying cell cycle entry.

9. (Original) An isolated polypeptide according to Claim 7 wherein said other molecule is a molecule capable of antagonizing cell survival.

10. (Original) An isolated polypeptide according to Claim 7 wherein said other molecule is a member of the Bcl-2 family.

11-20. (Canceled)

21. (New) The isolated polypeptide of claim 6, wherein said polypeptide is in homodimer or heterodimer form.

22. (New) A pharmaceutical composition comprising an isolated polypeptide according to any one of claims 6-10 or 21, and at least one of a pharmaceutically acceptable carrier or a diluent.